[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blepharitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blepharitis":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,59,90,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":41,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100643686","development-of-a-mobile-terminal-based-intelligent-detection-system-for-multiple-anterior-segment-diseases-of-the-eye-100643686",false,"NCT07634913","Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye","LENS","Inclusion Criteria:\n\n* Adults aged 18 years or older;\n* Willing to participate and able to provide written informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* Unable to cooperate with anterior segment image capture (including smartphone-based photography or slit-lamp biomicroscopy).",true,"ALL","18 Years",{"count":20,"type":21},3000,"ESTIMATED","OBSERVATIONAL","This is a multi-center, cross-sectional study evaluating a smartphone-based artificial intelligence (AI) system for anterior segment eye disease screening. The system is designed to identify 16 clinically important anterior segment conditions from images captured using a standard Android smartphone. A core design feature of the system is that all image analysis is performed entirely on the smartphone itself, without requiring internet connectivity or cloud-based server infrastructure.\n\nThe study is motivated by a structural challenge in the deployment of medical AI: systems that depend on cloud infrastructure for inference are non-functional in settings without reliable internet access, which disproportionately excludes populations in low-resource regions where the burden of preventable eye disease is highest. This study evaluates whether an on-device AI system, designed with operational constraints as a primary engineering objective, can deliver clinically acceptable diagnostic performance while remaining operable under real-world connectivity limitations.\n\nThe study comprises five evaluation components. First, the diagnostic performance of the AI system is benchmarked against board-certified ophthalmologists of varying seniority on a standardized set of smartphone-captured anterior segment images. Second, the usability of the system is evaluated among non-medical users who perform self-administered screening with minimal instruction, with per-screening time recorded across consecutive attempts to characterize the learning curve. Third, a head-to-head field trial directly compares the on-device AI system against a functionally equivalent cloud-based deployment of the same model architecture across key operational dimensions including screening duration, diagnostic performance, and user acceptability. Fourth, population-level screening is conducted among consecutively enrolled community residents at two low-resource sites, with per-disease sensitivity and specificity calculated against reference-standard slit-lamp examinations. Fifth, pre-specified health-economic and environmental analyses compare the two deployment modalities in terms of per-person screening cost, cost-effectiveness, per-inference electricity consumption, and projected carbon emissions at scale.\n\nThe reference standard for all diagnostic comparisons is slit-lamp biomicroscopic examination performed by board-certified ophthalmologists. The study is designed and reported in accordance with the DECIDE-AI reporting guideline for early-stage clinical evaluation of AI-driven decision-support systems.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Artifical Intelligence","Cataract","Pterygium","Keratopathy","Subconjunctival Hemorrhage","Conjunctivitis","Stye","Blepharitis","Entropion","Ectropion","Exophthalmos","Irregular Pupils","Conjunctival Concretions","Hyphema","Hypopyon","Corneal Transplant Status",[42,43,44,45],"Artificial Intelligence","Standalone Deployment","Smartphone","Eye Disease Screening","RECRUITING","2026-06-08",{"date":49,"type":50},"2026-06-09","ACTUAL",{"date":52,"type":50},"2023-12-12",{"date":54,"type":21},"2028-12",{"name":56,"class":57},"Zhongshan Ophthalmic Center, Sun Yat-sen University","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100626111","performance-and-safety-of-iridium-garze-in-blepharitis-or-blepharconjunctivitis-adjuvant-treatment-100626111","NCT07431385","Performance and Safety of IRIDIUM GARZE in Blepharitis or Blepharconjunctivitis Adjuvant Treatment","A Prospective, Multicentric, Open-label Clinical Investigation to Evaluate the Performance and Safety of the Use of IRIDIUM GARZE as Adjuvant Treatment in Patients With Blepharitis or Blepharoconjunctivitis","Inclusion Criteria:\n\n1. Patients having signed written informed consent to participate in the investigation obtained according to Good Clinical Practice (GCP) and International Organization for Standardization (ISO) 14155.\n2. Patients of either sex aged ≥ 18 years.\n3. Patients with a diagnosis of blepharitis or blepharoconjunctivitis in at least one eye assessed through slit lamp examination.\n4. Patients with Global Discomfort Score (GDS) ≥4 using the 0-10 numeric rating scale (NRS) ranging from 0 (no ocular discomfort) to 10 (worst ocular discomfort imaginable) in the target eye.\n5. Patients with an eyelid margin hyperaemia score ≥1 (as graded using a 4-point scale from 0: none to 4: severe) and at least three CDs at the base of the eyelashes in the target eye.\n6. TBUT ≤ 10 seconds in the target eye.\n7. Patients being able to comprehend the full nature and the purpose of the investigation, including possible risks and side effects, and patients able to cooperate with the Investigator and to comply with the requirements of the entire investigation (including ability to attend all the planned investigation visits according to the time limits), based on Investigator's judgment.\n8. Female patients must have a negative urine pregnancy test and use a highly effective form of contraception for at least one month prior to screening and throughout the investigation; or females must be surgically sterile, or postmenopausal as documented in medical history for at least one year. Highly effective birth control methods include combined hormonal contraception (containing oestrogen and progesterone) associated with inhibition of ovulation (oral, intravaginal, transdermal); progestogen only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device (IUD); intrauterine hormonereleasing system (IUS); bilateral tubal occlusion; vasectomised partner, sexual abstinence\\*.\n\n   * Note: According to the definition of Note 3 of ICH M3 Guideline highly effective methods of birth control are defined as those, alone or in combination, that result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. For patients using a hormonal contraceptive method, information regarding the product under evaluation and its potential effect on the contraceptive should be addressed.\n\nExclusion Criteria:\n\n1. Patients under treatment with any therapy that, based on Investigator's judgment, could interfere with the assessment of the performance or incidence of adverse events. Patients using tear substitutes can be enrolled in the investigation. Same eye drops and dosage should be maintained for the entire duration of the clinical investigation.\n2. Patients with presence or history of any systemic or ocular disorder, condition or disease (with particular attention to autoimmune \\[including but not limited to Sjogren's syndrome and rheumatoid arthritis\\], malignancies and neuro-oncological diseases, ocular trauma, ocular surgery) that, according to Investigator's judgment, can interfere with the conduction of the required investigation procedures or the assessment of the performance or the interpretation of the investigation results or the incidence of adverse events.\n3. Patients with hypersensitivity and\u002For allergy to any of the IRIDIUM GARZE components.\n4. Patients not giving their written informed consent.\n5. Patients participating in another clinical study\u002Finvestigation at the same time as the present investigation or within 30 days prior to screening visit.\n6. Patients who have history of drug, medication or alcohol abuse or addiction.\n7. Patients using contact lenses are allowed be included only if they agree to not use them for the entire duration of the investigation.",{"count":67,"type":21},80,"INTERVENTIONAL",[70],"NA","The study will evaluate the clinical improvement in ocular symptoms using IRIDIUM GARZE as adjuvant treatment in patients suffering of blepharitis or blepharoconjunctivitis as primary objective. The Change from baseline (T0) to Day 28 (T2) in overall ocular discomfort (Global Discomfort Score - GDS) using a 0-10 numeric rating scale (NRS) in the target eye. Subjects with a change from baseline to Day 28 (T2) at least equal to 30% of baseline value will be classified as responders. Also, secondary objectives will assess performance, physician evaluation, patient evaluation and safety of IRIDIUM GARZE.\n\nThis multicentric, prospective, open-label clinical investigation will aim to enrol 80 adult patients in about five sites located in Italy. Patients with diagnosis of blepharitis or blepharoconjunctivitis in at least one eye will be enrolled and will receive standard therapy plus IRIDIUM GARZEfor 28 days. Patients will be instructed to use IRIDIUM GARZE 4 times a day for 28 days on the target eye. Administration will take place at regular times during the day. In case that both the target eye and the contralateral eye are affected (or the contralateral eye will become affected during the investigation), administration of the investigational device will take place in both eyes. Patients will perform 3 visits on site: initial Screening\u002FBaseline Visit 1- T0 (Day 0); Visit 2-T1 (Day 14 \\[±2 days\\]) and Visit 3-T2 (Day 28 \\[+2 days\\]).",[32,73],"Blepharoconjunctivitis",[32,73,75,76,77,78],"Hyaluronic Acid","Dexpanthenol","Ocular discomfort","Periocular Hygiene","2026-02-23",{"date":81,"type":50},"2026-02-24",{"date":83,"type":50},"2025-09-17",{"date":85,"type":21},"2026-06",{"name":87,"class":88},"Fidia Farmaceutici s.p.a.","INDUSTRY",5,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":68,"phases":99,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100544623","photobiomodulation-with-red-vs-blue-light-rebel-100544623","NCT06371300","Photobiomodulation With REd vs BluE Light (REBEL)","Photobiomodulation of the Ocular Surface and Eyelids With Different Wavelengths: REd vs BluE Light (REBEL)","Inclusion Criteria:\n\n* Individuals with dry eye disease symptoms (Ocular Surface Disease Index questionnaire (OSDI) score ≥ 13 or Dry Eye Questionnaire (DEQ5) score \\> 6) and signs (tear film instability measured with non-invasive tear break-up time \\\u003C 10 s or ocular surface damage measured using special dyes placed on the front surface of the eyes that temporarily stains any aggravated or damaged cells: \\> 5 corneal spots, \\> 9 conjunctival spots or lid margin staining ≥ 2mm in length and ≥ 25% in width)\n* Individuals need to also have Meibomian gland dysfunction. The diagnosis of Meibomian gland dysfunction depends on how many of 5 glands in the central lower eyelid can express oil, and the quality of the oil. A diagnosis is made if there is decreased expressibility (grade 1-3 on the Pflugfelder scale) and reduced quality of oil (grade 1-3 on Bron scale). Any presence of gland blockage and\u002For loss of oil glands grade 1 to grade 4 of either eyelid \\[Pult and Reide-Pult, 2013\\]) will also justify a diagnosis of Meibomian gland dysfunction.\n* Individuals will also need to have ocular demodicosis, diagnosed by clinical observation on slit lamp biomicroscope based on signs including collarettes around the base of lashes, visible Demodex tails, or excessive pouting of lash follicles in those with good lid hygiene where Demodex was confirmed by secondary means such as visible Demodex tails.\n* Age ≥ 18 years, male or female\n* Able to provide written consent in English\n* Able to attend a total of 4 visits: 3 treatment visits and followed up for 1 month after final treatment\n\nExclusion Criteria:\n\n* Pregnancy\n* Ocular light-based therapies including intense pulsed light (IPL) or LLLT treatment within the past 1 month or during study period in addition to those provided in the study\n* Contact lens wear in the past 2 weeks or during study period\n* Other active ocular surface diseases or history of ocular surgery or corneal infections the past 6 months",{"count":98,"type":21},36,[70],"The use of photobiomodulation or low-level light therapy (LLLT) in the ophthalmic field stemmed from dermatology which has shown impact on skin blood flow and regeneration. There has been a rise in clinical interest with emerging evidence in the benefits of photobiomodulation in managing chronic inflammatory conditions such as dry eye disease including improvements in ocular discomfort symptoms, tear film stability and tear volume. Despite the observed clinical benefits, limited research has been done to compare photobiomodulation utilising different wavelengths, as most research on dry eye disease has focused on red wavelengths. It has been purported that blue wavelengths may disrupt microbial growth while red wavelengths stimulate energy production and hence increase heat in the affected tissues, although research into these differential impacts at the ocular surface and external eye has been limited. Hence, the aim of this exploratory clinical trial is to compare the impact of using LLLT incorporating red versus blue wavelengths on eyelid haemodynamics and microbiome, as well as conventional ocular surface measures of patients with dry eye disease and blepharitis (inflammation of the eyelids).\n\nParticipants with dry eye disease, oil gland disruption and blepharitis will receive 3 treatments with these LLLT, each separted by 1 week apart, and followed up to 1 month after the final treatment session. Participants will be randomised to either of 3 groups: Red light only group, Red + Blue light group, or a sham treatment group.",[102,103,32],"Dry Eye Syndromes","Meibomian Gland Dysfunction",[105],"Low-level light therapy","2026-01-19",{"date":108,"type":50},"2026-01-21",{"date":110,"type":50},"2024-05-01",{"date":112,"type":21},"2026-12-30",{"name":114,"class":57},"Aston University",2,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":68,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100408803","evaluation-of-summit-brush-in-treatment-of-blepharitis-100408803","NCT04603222","Evaluation of SUMMIT BRUSH in Treatment of Blepharitis","Inclusion Criteria:\n\n* Clinical signs and symptoms of blepharitis (Staphylococcal and Demodex).\n* Must exhibit visible collarettes, clear sleeves, and scurfs on the eyelid margins upon Slit Lamp Biomicroscopy.\n\nExclusion Criteria:\n\n* Hordeolum\n* Chalazion\n* Periorbital cellulitis\n* Allergic eyelid dermatitis.\n* Acute bacterial conjunctivitis\n* Open periorbital wounds.",{"count":123,"type":21},60,[70],"Dry Eye Disease (DED) is a multifactorial disease that affects \\~15-30 million people in the USA alone. It creates an enormous societal and economic burden, decreases productivity in the workplace, and affects the quality of lives of the people affected by this disease. DED is primarily caused by blepharitis, a chronic inflammation of the eyelid margins. If left untreated, blepharitis results in the obstruction and loss of the glands responsible for tear film production. The standard of care is the use of self-administered at home commercially available products, e.g., eyelid foams, gels, and pads. Although these products are helpful, they have limitations. Patients often require expensive in office procedures, e.g., lid debridement with exfoliation devices or more expensive procedures. The scope of this project is to evaluate the effectiveness of a new self-administered disposable ocular brush used in conjunction with the most common eyelid cleanser. The investigators are looking to see if combining the microexfoliation provided by the brush with the eyelid cleanser is more effective at removing the eyelid debris than the cleanser alone.",[32],"2020-11-24",{"date":129,"type":50},"2020-11-27",{"date":131,"type":50},"2020-07-21",{"date":133,"type":21},"2022-07-18",{"name":135,"class":57},"University of Notre Dame",3]